Gut bacteria could help revive immunotherapy in lung cancer

NCT ID NCT06448572

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tests whether a capsule containing a healthy gut bacterium (EXL01) can boost the effectiveness of the immunotherapy drug nivolumab in people with advanced non-small cell lung cancer that has stopped responding to prior immunotherapy. The study will enroll 21 adults whose cancer has progressed after standard treatments. Researchers will monitor how long the cancer stays under control and track any side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
EXL01 (a single strain of the gut bacterium Faecalibacterium prausnitzii) combined with nivolumab
What this could lead to
If it works, this could point toward a new treatment option for people with advanced lung cancer whose disease has stopped responding to standard immunotherapy.
What could go wrong
This is a very early, small pilot study with only 21 participants, so results may not apply to everyone. The combination may not improve outcomes and could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • CHU Lille

    RECRUITING

    Lille, 59000, France

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.